Carle Cancer Center NCI Community Oncology Research Progran (NCORP)

描述(由申请人提供)：为了响应RFA-CA-13-013，Carle癌症中心，一个有30年历史的社区临床肿瘤学计划，正在申请资金，以继续其坚定的承诺，在社区环境中推进和提供癌症预防、控制、筛查和治疗研究。敬业的员工和高质量和及时数据的强大历史，所有这些都经常超过应计目标，为Carle赢得了今天的声誉。在推进癌症护理提供研究(CCDR)方面，Carle的优势是一个从上到下(组织和电子)高度集成的卫生保健系统，由370多名初级保健和专科医生组成，所有人都投资于研究文化。除此之外，还有一项覆盖多个州的大型电子保险计划，以及以农村为主、服务不足的服务人群。Carle社区中一个以前未开发的资源，由NIH大量资助的伊利诺伊大学，有着类似的一致利益，并正在将Carle癌症中心的研究倡议和洞察力推向更高的水平。Carle的主要举措之一是剖析和分析周围服务不足的农村人口，以便制定正确的问题并解决正确的护理障碍。了解干预的“目标”可能有助于CCDR作为一个整体。Carle的才华横溢且经验丰富的研究团队，基于在NCI启动的临床试验的多年经验，迅速获得了在癌症护理提供研究方面取得成效和成功所需的技能。CCDR应计项目已经占到了去年总应计项目的一半。Carle癌症中心预计，随着研究型专业外科医生和内科医生的增加，癌症治疗的贡献将会增加。医生和工作人员对癌症现场的专业化、质量倡议、多个多学科肿瘤委员会、参与成像倡议和生物样本试验的能力所有这些都证明，研究治疗方案将是最优先的。伊利诺伊州奥罗拉的Rush-Copley医疗中心和印第安纳州密歇根市的Franciscan St.Anthony Health将加入我们的努力。两者都带来了多年的合作经验，并为愿意参与癌症护理提供研究的人群提供服务。总而言之，历经多年的研究企业实力雄厚，数据质量优良，监管流程广泛且无可挑剔。

DESCRIPTION (provided by applicant): In response to RFA-CA-13-013, the Carle Cancer Center, a 30 year legacy Community Clinical Oncology Program, is applying for funding to continue its strong commitment to advance and provide cancer prevention, control, screening, and treatment research in the community setting. Dedicated staff and a strong history of high quality and timely data, all while often exceeding accrual goals, has earned Carle the reputation that it has today. Moving forward with cancer care delivery research (CCDR), Carle's strength is a health care system that is highly integrated from top to bottom (organizationally and electronically), comprised of over 370 primary care and specialty physicians all invested in a research culture. Adding to that is a large electronically accessible insurance plan spanning multiple states and a service population that is largely rural and underserved. One previously untapped resource in the Carle community, the heavily NIH funded University of Illinois, has similar aligned interests and is pushing the Carle Cancer Center research initiatives and insight to even higher levels. One of Carle's chief initiatives is to dissect and analyze the surrounding underserved rural population in order to formulate the right questions and address the correct barriers to care. Learning the "targets" for intervention may facilitate CCDR as a whole. Carle's talented and experienced research team, based on years of experience in NCI initiated clinical trials, has rapidly acquired the skills needed to be productive and successful in cancer care delivery research. Already CCDR accrual accounts for one half of last year's total accrual. Carle Cancer Center projects an increase in cancer treatment contributions with the addition of research oriented specialty surgeons and physicians. Cancer site specialization by physicians and staff, quality initiatives, multiple multidisciplinary tumor boards, an ability to participatein imaging initiatives and bio specimen trials all attest that research treatment options will take te highest priority. Joining in our efforts will be component institutions, Rush-Copley Medical Center in Aurora, Illinois and Franciscan St. Anthony Health in Michigan City, Indiana. Both bring many years of collaborative experience and serve populations that would embrace participation in cancer care delivery research. Together, the research enterprise through the years is strong, data quality is excellent, and regulatory processes are extensive and impeccable.